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An accurate, simple, and direct test for
tuberculosis (TB) has been a priority for
many years, but to date no such test has
become available. Easily detectable sensi-
tive and specific biomarkers are elusive
and may remain so. In parallel to the
essential extensive efforts in biomarker
discovery performed in this field, we
suggest it is also worthwhile to evaluate
the utility of biomarkers of TB infection in
a ‘‘treat-to-test’’ strategy. Biomarkers of
TB infection already identified or detected
in ongoing systematic studies that are not
useful for simple near-patient tests may
nonetheless be suitable in a treat-to-test
strategy. Thus, we call for the investigation
of the kinetics of these biomarkers during
the early phase of treatment.
Background
To date no simple, rapid, accurate test
for TB has been developed. An effective
immunologic lateral flow assay able to test
blood, urine, or conceivably sputum would
be a major step forwards. However, assays
based on antibody detection, although
highly effective for other diseases, have a
dismal record for TB diagnostics in spite of
decades of dedicated research. In recent
years, a selection of the then available
antibody-based assays were tested and
shown to have no value for the diagnosis
of active TB [1]. The situation with
antigen-based assays may be more prom-
ising, but even with these assays progress
has been limited. Antigens with acceptable
specificity have been identified and tests
are available to detect them, but the
sensitivity is generally low. Notably, the
detection of mycobacterially derived li-
poarabinomannan (LAM) in urine has
been shown to be specific, but, except
possibly in specific groups of patients
(HIV-infected with low CD4 counts), the
sensitivity is currently far too low to
replace microscopy [2]. As recently re-
viewed by McNerney and Daley (2011)
[3], there is not only a need for new
biomarkers, but also new detection tech-
nologies.
Because of these obstacles, molecular
methods based on DNA amplification
have been increasingly developed and
applied. This work has resulted in a
number of highly effective and innovative
assays with excellent performance [4].
Unfortunately, DNA amplification tech-
nologies are fundamentally more complex
than, for example, a lateral flow-based
immunological assay. Thus, providing and
maintaining molecular testing where it is
most needed will be a huge logistical and
financial challenge.
For this reason, there remains consid-
erable effort invested in identifying suit-
able human and mycobacterial biomark-
ers for use in a simple and rapid
immunological assay. Indeed, state of the
art detection and bioinformatics tech-
niques are now being applied systemati-
cally for this purpose. Recently, Berry et
al. (2010) [5] published a detailed tran-
scriptional analysis of the human response
to mycobacterial infection and identified
transcriptional signatures that appear to
be associated with TB infection and
different stages of infection. An analysis
of the dominant proteins present during
different phases in a Mycobacterium tubercu-
losis infection model in guinea pigs was
recently published by Kruh et al. (2010)
[6], and proteomic analysis revealed that
highly immunogenic TB antigens were
released in exosomes of TB-infected mac-
rophages [7]. Kunnath-Velayudhan et al.
(2010) [8] studied the antibody response of
patients at different stages of the disease
and documented marked antibody target
preferences between patients, as well as a
correlation of the response with disease
burden.
These efforts to characterize antibodies
and other indicators of TB disease are
essential, but the failure to date to identify
a diagnostic biomarker, admittedly with
less sophisticated tools, suggests to us that
discovery of suitable biomarkers and the
development of a useful test for near-
patient diagnostic use in the immediate
future is far from certain. That is why we
would like to take this opportunity to call
for the consideration of the investigation of
a parallel pragmatic strategy that may
allow the development of a clinically useful
assay in a shorter period.
Discussion
We would like to suggest that the use of
immunological assays be considered in a
treat-to-test strategy. In this approach, TB
suspects would be started on treatment
empirically, and after a number of days, a
test would be performed to measure
mycobacterial or host biomarkers.
There is evidence available supporting
this proposition. A proportion of patients
beginning TB treatment suffer a so-called
paradoxical response, which is presumably
an immunological reaction to the burst of
mycobacterial antigens released when
treatment starts [9,10].
Mattos et al. (2010) [11] recently
investigated the levels of specific anti-
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3 or 6 months of treatment. They
identified an increase in serum levels of
antibodies against an intracellular anti-
gen (the 16-KDa alpha crystallin) during
therapy in many patients. This antibody
response presumably followed the re-
lease of intracellular mycobacterial anti-
gens as a result of the initial wave of
bacterial killing. Indeed, it has been
established that upon initiation of ap-
propriate TB therapy, the majority of
t h em y c o b a c t e r i ap r e s e n ta r ek i l l e di n
the first few days of therapy [12].
Measurement of antigens during the
peak of bacterial killing (Figure 1), and
thus antigen release, would in principle
reduce the analytical sensitivity required
for direct testing at presentation.
We also expect antibody titers to rapidly
increase upon release of TB antigens, as
the immune system will have been primed
during initial infection (Figure 1). A
relative increase in anti-TB antibody levels
occurring after a short treatment period
would also be indicative of true infection
and effective therapy. The shift towards
antibodies against intracellular TB anti-
gens shown by Mattos et al. (2010) [11]
during successful therapy strongly supports
this. The timing of this response is yet to
be determined and would be most inter-
esting diagnostically if changes are detect-
able within 1 or 2 weeks. As antibody
profiles of TB patients have been shown to
vary considerably between patients [8],
antibody testing may not be straightfor-
ward and may require multiplex testing.
Currently, due to the lack of better
diagnostic tools, TB suspects are often
empirically prescribed a short course of
broad spectrum antibiotics in an attempt
to rule out TB. A presumptive diagnosis of
TB is made only if the symptoms remain.
This ‘‘rule-out’’ strategy causes further
delay for TB patients requiring anti-TB
treatment. Also, due to the frequent
inappropriate prescription of fluoroquino-
lones as broad spectrum antibiotics, there
is a serious danger of increased resistance
to fluoroquinolones, which are valuable
second-line TB drugs [13]. Increased
fluoroquinolone resistance has already
been detected in India [14] and other
countries. Our suggested ‘‘rule-in’’ strate-
gy would avoid treatment delay and avoid
possible mono-therapy with potential sec-
ond-line drugs but would result in a
number of non-TB patients receiving a
few doses of multidrug TB treatment for
testing.
In many locations, a significant propor-
tion of patients are started on a full course
of TB therapy on the basis of clinical
suspicion without bacteriological confir-
mation. This occurs both in high-income
and low-income settings [15–18], and only
in some cases after a long period is therapy
reevaluated.
We are aware that our suggested treat-
to-test strategy is not the ideal ‘‘rapid’’ test,
and, for example, would likely fail in
patients with multidrug-resistant (MDR)
or monoresistant TB strains, as these may
not be differentiated from non-TB pa-
tients. Additionally, in some situations
patients may be infected with multiple
genotypes [19], one of which is MDR, and
in this case initial killing of the sensitive
isolate may result in a positive signal for
this type of test. However, it should be
noted that this type of mixed infection is
also not easily identified using molecular
methods. It was recently reported that the
Xpert MTB/RIF assay requires between
65% and 100% of the DNA present to be
derived from a resistant isolate to detect
rifampicin resistance [20].
Nonetheless, a test that could detect
treatment response, if applied in a differ-
ent way, is in fact highly desirable, as
patients known to be infected with TB but
receiving ineffective therapy could be
identified. It could also be envisioned that
the extent of killing is reflected in the
biomarker response, and susceptibility to
Figure 1. Schematic representation of the expected release of TB antigens and consequential host antibody response upon
initiation of treatment. We propose that measurement of these increased levels can be useful for diagnosing TB in a treat-to-test strategy.
doi:10.1371/journal.ppat.1002207.g001
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results in an intermediate response. This
would ultimately mean that a biomarker
response could be used to classify patients
as either having susceptible TB, (M)DR-
TB, or no TB. Thus, a negative result or
weak response in a treat-to-test strategy
could also be used to initiate further
investigation for other diseases as well as
testing for MDR-TB.
As a treat-to-test strategy would involve
an additional visit to a diagnostic centre, as
opposed to one-stop microscopy [21] or a
true rapid near-patient test, there remains
a risk of dropout during the diagnostic
procedure. This is also true for culture and
microscopy performed on multiple sam-
ples. And it should be noted that the use of
broad spectrum antibiotics—particularly
as agents are often inappropriately select-
ed with activity against M. tuberculosis—has
been shown to result in a delay in starting
multidrug treatment [22], as well as
inevitably some loss to follow up.
In summary, although a true direct test
for TB remains a priority, biomarkers
identified in ongoing systematic studies
may not in the short term lead to assays
with the required sensitivity and specific-
ity. Nonetheless, we believe some of these
biomarkers may be suitable in a treat-to-
test strategy, so we encourage measure-
ment of their kinetics during the early
phase of treatment.
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